Abstract
Systemic sclerosis (scleroderma, SSc) is a chronic connective tissue disease of unknown etiology characterized by progressive fibrosis of the skin and a distinctive pattern of internal organ involvement. Excessive fibrosis, vascular injury, autoimmunity and inflammation are permanent features of the disease process leading to irreversible organ damage and significant morbidity and mortality in SSc patients. Recent progress in understanding the pathogenesis of SSc as well as diagnostic and therapeutic advances in medicine have made more effective treatment strategies possible. So far, therapies targeting vascular aspects of SSc have been most successful. This underlines the role of vascular injury in the pathogenesis of the disease and raising hopes of significant improvement in the management of SSc patients. The aim of this review is to summarize recent and potential future treatments of SSc-associated vascular disease.
Keywords: Systemic sclerosis, vascular disease, management
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Targeting Vascular Disease in Systemic Sclerosis
Volume: 6 Issue: 4
Author(s): Otylia Kowal-Bielecka
Affiliation:
Keywords: Systemic sclerosis, vascular disease, management
Abstract: Systemic sclerosis (scleroderma, SSc) is a chronic connective tissue disease of unknown etiology characterized by progressive fibrosis of the skin and a distinctive pattern of internal organ involvement. Excessive fibrosis, vascular injury, autoimmunity and inflammation are permanent features of the disease process leading to irreversible organ damage and significant morbidity and mortality in SSc patients. Recent progress in understanding the pathogenesis of SSc as well as diagnostic and therapeutic advances in medicine have made more effective treatment strategies possible. So far, therapies targeting vascular aspects of SSc have been most successful. This underlines the role of vascular injury in the pathogenesis of the disease and raising hopes of significant improvement in the management of SSc patients. The aim of this review is to summarize recent and potential future treatments of SSc-associated vascular disease.
Export Options
About this article
Cite this article as:
Kowal-Bielecka Otylia, Targeting Vascular Disease in Systemic Sclerosis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/187153006779025793
DOI https://dx.doi.org/10.2174/187153006779025793 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Identifying the Metabolic Syndrome in Obese Children and Adolescents: Do Age and Definition Matter?
Current Clinical Pharmacology Cardiovascular Disease: An Economical Perspective
Current Pharmaceutical Design Editorial [Hot Topic: Pathogenesis and Treatment of Diabetic Complications,Retinopathy, Nephropathy and Cardiomyopathy (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design RAAS Inhibition and Renal Protection
Current Pharmaceutical Design Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Critical Illness in Obstetric Patients: Introduction and Epidemiology
Current Women`s Health Reviews Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications
Current Pharmaceutical Design Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Development of Pyrazole Compounds as Antidiabetic Agent: A Review
Letters in Drug Design & Discovery Inflammatory Systemic Biomarkers in Setting Acute Coronary Syndromes - Effects of the Diurnal Variation
Current Drug Targets Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS
Current Pharmaceutical Biotechnology Dietary Fat and Hypertension: A Novel Approach Through the Proteolytic Regulatory Enzymes of the Renin-Angiotensin-System
Cardiovascular & Hematological Agents in Medicinal Chemistry Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design Pharmacological Approaches of Alzheimer's Disease: An Update
Current Drug Therapy Neuronal Nitric Oxide Synthase and Sympathetic Nerve Activity in Neurovascular and Metabolic Systems
Current Neurovascular Research